The recent British pound depreciation is a big Brexit barometer.

Apple Boston

2019-08-20 07:33:00 Tue ET

The recent British pound depreciation is a big Brexit barometer. Britain appoints former London mayor and Foreign Secretary Boris Johnson as the prime minister. The Conservative Party selects Johnson as the successor to Theresa May to set the stage for fresh Brexit negotiations with the European Commission. This change hits the pound with volatile exchange rate gyrations. The British pound sinks to the new lowest level of US$1.24 in 2017-2019. Johnson advocates that he would be keen to force Brexit with or without a post-May deal on October 31, 2019, which is the latest deadline for Britain to depart the European Union. Alternatively, Britons might consider a second referendum on Brexit with the backstop agreement for free flows of goods between Northern Ireland and the Irish Republic.

Most stock market analysts predict that leaving the European Union with no proper deal would plunge the U.K. into a deep economic recession due to Eurozone trade constraints and capital outflows. U.K. stock markets would fall 5% in light of a 2% decrease in economic output, and the pound would likely plummet 10%-13%. This prediction accords with what the U.K. Office for Budget Responsibility suggests in its recent report on the British economic outlook.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

New computer algorithms and passive mutual fund managers now run the stock market.

Joseph Corr

2019-11-17 14:43:00 Sunday ET

New computer algorithms and passive mutual fund managers now run the stock market.

New computer algorithms and passive mutual fund managers run the stock market. Morningstar suggests that the total dollar amount of passive equity assets re

+See More

The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and governments.

Jonah Whanau

2019-11-15 13:34:00 Friday ET

The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and governments.

The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and go

+See More

American unemployment declines to the 50-year historical low level of 3.5% with moderate job growth.

Chanel Holden

2019-11-19 09:33:00 Tuesday ET

American unemployment declines to the 50-year historical low level of 3.5% with moderate job growth.

American unemployment declines to the 50-year historical low level of 3.5% with moderate job growth. Despite a sharp slowdown in U.S. services and utilities

+See More

Berkeley macro economist Brad DeLong sees no good reasons for an imminent economic recession with mass unemployment and even depression.

Laura Hermes

2019-11-21 11:34:00 Thursday ET

Berkeley macro economist Brad DeLong sees no good reasons for an imminent economic recession with mass unemployment and even depression.

Berkeley macro economist Brad DeLong sees no good reasons for an imminent economic recession with mass unemployment and even depression. The current U.S. ec

+See More

Many billionaires choose to live below their means with frugal habits and lifestyles.

Chanel Holden

2019-12-04 14:35:00 Wednesday ET

Many billionaires choose to live below their means with frugal habits and lifestyles.

Many billionaires choose to live below their means with frugal habits and lifestyles. Those people who consistently commit to saving more, spending less, an

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More